Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Didier Saur"'
Autor:
Anne Hickman, Susan Zhou, Didier Saur, Steven G. Terra, David L. Cutler, Vaishali Sahasrabudhe, Kyle Matschke, Sangeeta Raje, Haihong Shi
Publikováno v:
Clinical Therapeutics. 40:1701-1710
Purpose Ertugliflozin, an oral, highly selective inhibitor of the sodium-glucose cotransporter 2, is approved in the United States and the European Union for the treatment of adults with type 2 diabetes mellitus. Hepatic impairment may affect, to var
Autor:
Vikas Kumar Dawra, Didier Saur, David L. Cutler, Anne Hickman, Steven G. Terra, Yali Liang, Vaishali Sahasrabudhe, Kyle Matschke, Haihong Shi
Publikováno v:
Clinical Therapeutics. 40:1538-1547
Purpose Ertugliflozin is a selective sodium glucose cotransporter 2 inhibitor being developed for the treatment of type 2 diabetes mellitus. The primary enzyme involved in the metabolism of ertugliflozin is uridine diphosphate-glucuronosyltransferase
Autor:
Klaas Schildknegt, Eric Fluhler, Lloyd Stevens, Eric Woolf, Alfin D. N. Vaz, Haihong Shi, Steven G. Terra, Dimitris Papadopoulos, Vaishali Sahasrabudhe, Didier Saur, Daniel Gaunt, Kyle Matschke, Robert J. Fountaine, Susan Zhou, David L. Cutler, Ernesto Callegari, Sangeeta Raje, Christine Alvey
Publikováno v:
Clinical and Translational Science. 11:405-411
Ertugliflozin, a sodium glucose cotransporter-2 inhibitor, is approved in the United States for treatment of type 2 diabetes mellitus. A novel two-period study design with 14 C microtracer dosing in each period was used to determine absolute oral bio
Autor:
D. L. Cutler, Z. Zhou, Didier Saur, Harry Shi, Melissa O'Gorman, Anne Hickman, Steven G. Terra, Vaishali Sahasrabudhe
Publikováno v:
The Journal of Clinical Pharmacology. 57:1432-1443
Ertugliflozin is a highly selective and potent inhibitor of the sodium-glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus. The glycemic efficacy of sodium-glucose cotransporter 2 inhibitors such as ertugliflozin depe
Autor:
Gregory T. Golm, Kristen Focht, Steven G. Terra, Brett Lauring, Didier Saur, Jeremy Johnson, Samuel Dagogo-Jack, Melanie J. Davies, Giuseppe Derosa, Juan P. Frias, Amanda Darekar
Publikováno v:
Diabetes, Obesity and Metabolism. 19:721-728
Aims To conduct a phase III study to evaluate the efficacy and safety of ertugliflozin monotherapy in people with type 2 diabetes. Materials and methods This was a 52-week, double-blind, multicentre, randomized, parallel-group study with a 26-week, p
Autor:
Steven G. Terra, Raluca Pascu, Bernard Charbonnel, Didier Saur, Susan Huyck, Amanda Darekar, Dénes Páll, Juan P. Frias, Harry Shi, Brett Lauring, Julio Rosenstock
We evaluated the efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2 diabetes mellitus (T2DM) inadequately controlled (HbA1c, 7.0%-10.5%) with metformin monotherapy (≥1500 mg/d for ≥8 weeks).This was a double-blind, 26-week, multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea840a427b6241ac27c016a7369edccf
Autor:
Anne Hickman, Didier Saur, Isabelle Huyghe, Haihong Shi, Vaishali Sahasrabudhe, Kyle Matschke, David L. Cutler, Steven G. Terra
Publikováno v:
Clinical pharmacology in drug development. 7(5)
Ertugliflozin, a selective sodium-glucose cotransporter-2 inhibitor, is being developed for the treatment of type 2 diabetes mellitus. This randomized, 6-sequence, 3-period crossover study assessed the effect of ertugliflozin (100 mg; supratherapeuti
Autor:
Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, Tsutomu Takeuchi, Tadashi Nakamura, Galina Matsievskaia, Barbara Hunt, Thomas Wagner, Bernard Souberbielle, for the NEXUS Study Group
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-13 (2019)
Abstract Background Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), was evaluated in a phase II randomized, double-blind, placebo-controlled stud
Externí odkaz:
https://doaj.org/article/2a809e0128b548da80279d3a1a9e0751
Publikováno v:
Energies, Vol 9, Iss 11, p 912 (2016)
Heat sources, such as power electronics for offshore power, could be cooled passively—mainly by conduction and natural convection. The obvious advantage of this strategy is its high reliability. However, it must be implemented in an efficient manne
Externí odkaz:
https://doaj.org/article/0047538d77b74de291422014c53d2add